The ABCD nationwide degludec audit is an independent audit supported by an unrestricted grant from Novo Nordisk Ltd

ABCD nationwide degludec audit – first visit data collection form



Clinician		Centre					
Patient Identification							
İ	NT LABEL HERE OR gender and date of birth below	White	☐ British☐ Irish☐ Any Other White Background				
Patient name		 Mixed	□ White and Black Caribbean □ White and Black African □ White and Asian □ Any Other Mixed Background				
Gender Male Date of birth	Female (circle one)	Asian or Asian British	☐ Indian ☐ Pakistani ☐ Bangladeshi ☐ Any Other Asian Background				
	/ / (dd/mm/yyyy)	Black or Black British	☐ Caribbean ☐ African ☐ Any Other Black Background				
Date of visit / /	(dd/mm/yyyy) Age	Other Ethnic Groups	☐ Chinese ☐ Any Other Ethnic Group ☐ Not stated				
Patient Characteristics							
Duration of diabetes (in years) at t	his visit year	rs					
Type of diabetes Type 1	Type 2 Other	(circle one) If other pl	ease specify:				
HbA1c	please enter either %	0	mmol/mol Da	ate of test			
Date of blood test							
Blood pressure SBP mmH	g	Blood pressure DB	P mmHg Da	ate of test			
Triglyceride mmol		HD		ate of test			
Total cholesterol mmol	/L Date of test	Serum creatinin		ate of test			
Height m BMI will be auto-calculated when data is	entered into online audit form	Current weigh		ate of test			
	Ala	nine aminotransferase AL	.T U/L Da	ate of test			
Rationale for starting degludec?							
Problems with hypoglycaemia	Yes No (circle one) Poor (compliance, e.g. need	flexible injection timing	Yes No (circle one)			
Need more than 80 IU/day	Yes No (circle one) Needs	s OD basal insulin		Yes No (circle one)			
Considering going into a pump		in with variably timed minister (e.g. district n		Yes No (circle one)			
Intrasubject variability of glucoses with current basal insulin	Yes No (circle one) If other	er please specify					
Current Medications							
Patient already on insulin?	Yes No (circle one))					
If patient is already on insulin, ple	ase answer the next 3 questions						
Injection site problems?	Yes No (circle one) Details					
At what level does the patient kno	w they are going low? No	t at all <3m	mol/L 3mmol/L or	greater (circle one)			
Assessment of awareness of hypog Does the patient know when hypo		2 3	4 5 6	7 (circle one)			
	(1) Always A	ware		(7) Never Aware			

Please circle the drugs that the patient is on										Total Dose	
Biguanides	Drug name	Metformin Enter total dose including that in combination tablets							mg/day		
Sulfonylureas	Drug name	Chlorpropamide	Glibenclamide	Gliclazide	Gliclazide	MR Glick	azide SR	Glimepiride	Glipizide		mg/day
TZDs & TZDs with metformin	Drug name	Pioglitazone	Pioglitazone + n	netformin	osiglitazone	Rosiglitazo	one + metformi	n Enter	only dose of TZD		mg/day
Meglitinides	Drug name	Nateglinide	ateglinide Repaglinide								
Alpha-glucosidase inhibitors	Drug name	Acarbose	arbose								
GLP-1 agonist	Drug name	Exenatide	Liraglutide	Exenatide (on	ice-weekly)	Exenatide	qw Lixiser	natide			mg/day
SGLT2 inhibitors	Drug name	Dapagliflozin	Canagliflozin	Empagliflozin							mg/day
DPP-4 inhibitors and DPP-4 inhibitors with metformin	Drug name	Alogliptin Saxagliptin Vildagliptin	Alogliptin + m Saxagliptin + m Vildagliptin + n	netformin	Linagliptin Sitagliptin ter only dose		in + metformir				mg/day
Insulin – rapid/short acting	Drug name	Insulin aspart	Insulin glulisine	Insulin lispro							units/day
Insulin – long/ intermediate acting	Drug name	Insulin detemir	Insulin glargine	Insulin zinc sus	spension						units/day
Insulin – biphasic	Drug name	Biphasic insulin	aspart Biph	nasic insulin lispro	Biphas	c isophane ins	ulin				units/day
Insulin – pump therapy Drug name Human soluble insulin Insulin aspart Insulin glulisine									units/ 24hrs Basal insulin rate		
		Insulin lispro	Porcine soluble in	Other							units/ 24hrs Bolus insulin amount
Other antidiabetic medications which could affect glycaemic of		S Drug nai	me								mg/day
Anti-obesity medication	Drug name	Orlistat	Sibutramine								mg/day
Hypoglycaemia Histo Please give best estimate average 2 mild hypos per the last 12 months.	. For examp						Number in		Number in last 6 months		Number in last 3 months
Minor			D				12 11011	1113	O IIIOITUIS	1	3 months
Self-treated (symptoms/glucose values not required) Severe 3rd party intervention (defined as patient could not have self-treated. Excludes cases where a patient could have self-treated but a kind person helped)											
Nocturnal Either minor or severe, 00:00 to 06:00											
Severe Episodes Episode Details Episode Number											
Episode Det	.diis		1	2					4		F
Blood Glucose value (m	mol/L)			2		3	,		4		5
Symptoms Re	emembered	Yes	No	Yes	No	Yes	No	Yes	No		Yes No
many as apply)	patient eported by d Party	Yes		Yes	No	Yes	No	Yes	No		Yes No

	Confused	Yes No				
	Semi- conscious	Yes No				
	Unconscious	Yes No				
	Not known	Yes No				
Treatment (choose as	Family member/friend	Yes No Not known				
many as apply)	Ambulance call out	Yes No Not known				
	Hospitalisation	Yes No Not known				
	Required oral glucose	Yes No Not known				
	Required IM glucagon	Yes No Not known				
	Required IV glucose	Yes No Not known				

Please use blank paper for additional severe episodes

Initiation (of Degludec										
Start dose		units/day	,								
Who will adr	minister degludec?	Health profe	ssional	Other Pat	ient	Relative (ci	rcle one) If other	please spe	cify:		
Proposed time of degludec administration:		Afternoon	Evening/be	edtime Lun	chtime	Morning	Variable (circle one)	If variable please spe	cify:		
Date of initia	ation of degludec:	/	/	(dd/mm/yyyy)							
Change in ot medication?	her antidiabetic	Yes	No	(circle one)							
(If you are discont	tinuing another long/ intermed	diate acting insulin, o	choose Yes)								
If yes, please	indicate change belo	N					New Dose	No Change	Change Dose	Added	Stopped/ Switched
Biguanides	Drug name	Metformin	Enter total dos	e including that in	combina	tion tablets	mg/day				
Sulfonylureas	Drug name	Chlorpropamide	Glibenclamid	le Gliclazide	Gl	iclazide MR					
		Gliclazide SR	Glimepiride	Glipizide			mg/day				
TZDs & TZDs wi	th metformin Drug name	Pioglitazone	Pioglitazone	e + metformin							
		Rosiglitazone	Rosiglitazon	e + metformin	Enter only	dose of TZD	mg/day				
Meglitinides	Drug name	Nateglinide	Repaglinide	2			mg/day				
Alpha-glucosid	ase inhibitors Drug name	Acarbose					mg/day				
GLP-1 agonist	Drug name	Exenatide	Liraglutide	Exenatide ((once-we	ekly)					
		Exenatide qw	Lixisenatide	2			mg/day				
SGLT2 inhibitor	S Drug name	Dapagliflozin	Canagliflozi	n Empaglifloz	rin		mg/day				
DPP-4 inhibitor inhibitors with		Alogliptin	Alogliptin	+ metformin	Linagl	liptin					
		Linagliptin + r	metformin	Sitagliptin + m	etformin						
		Sitagliptin	Saxagliptir								
		Vildagliptin	Vildagliptir		Enter only inhibitor	y dose of DDP-4	mg/day				

Insulin – rapid/short acting	Drug name	Insulin aspart Insulin glulisine Insulin lispro	units/day	
Insulin – long/ intermediate acting	Drug name	Insulin detemir Insulin glargine Insulin zinc suspension	units/day	
Insulin – biphasic	Drug name	Biphasic insulin aspart Biphasic insulin lispro		
		Biphasic isophane insulin	units/day	
Insulin – pump therapy	Drug name	Human soluble insulin Insulin aspart Insulin glulisine Insulin lispro Porcine soluble insulin Other	Basal insulin rate Units/ 24hrs Bolus insulin amount	
Other antidiabetic medications or medications which could affect glycaemic control	Drug name		mg/day	
Anti-obesity medication	Drug name	Orlistat Sibutramine	mg/day	